x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

PACUPod: Oncology

Pharmacy & Acute Care University

PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across oncology, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in

health & fitness medicine

All Episodes

7:50

Effects of Metformin on Survival and Toxicity in...

PACUPod: Oncology ·

2025/09/15

en

6:04

Immune mediated adverse events in the randomized...

PACUPod: Oncology ·

2025/09/03

en

0:17

Belantamab mafodotin plus bortezomib and...

PACUPod: Oncology ·

2025/09/03

{"episode_title": "DREAMM-7 Updated Overall Survival: Belantamab Mafodotin with BVd in Relapsed/Refractory Multiple Myeloma", "podcast_show": "PACUPod", "description": "In this episode of PACUPod, we review the updated overall survival results from the DREAMM-7 phase 3 trial, testing belantamab mafodotin in combination with bortezomib and dexamethasone (BVd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma. We discuss the significant

en

7:47

Brentuximab vedotin plus chemotherapy for the...

PACUPod: Oncology ·

2025/09/03

{ "episode_title": "ECHELON-2 5-Year Follow-Up: Brentuximab Vedotin Plus CHP in Frontline sALCL", "episode_description": "In this PACUPod episode, Britany and Seth dissect the five-year subgroup analysis of the ECHELON-2 trial focused on frontline systemic anaplastic large cell lymphoma (sALCL). They compare brentuximab vedotin plus CHP (BV+CHP) against CHOP in untreated CD30-positive PTCL, highlighting long-term efficacy and safety. Key findings include progression-free survival not

en

6:04

Virtual reality for outpatient management of cancer...

PACUPod: Oncology ·

2025/09/03

In this PACULit update, Britany and Seth discuss Groninger and colleagues' pilot study on using virtual reality (VR) as a nonpharmacologic adjunct for outpatient management of chronic cancer pain. The single-arm trial enrolled 33 adult outpatients with persistent cancer pain to evaluate a phased VR dosing regimen over three weeks using the Meta Quest 2 headset. Primary outcome was pain intensity (numeric rating scale); secondary outcomes included PROMIS pain interference, patient

en

5:58

Enhanced CAR T-Cell Therapy for Lymphoma after...

PACUPod: Oncology ·

2025/09/03

en

7:59

Overall Survival with Inavolisib in PIK3CA-Mutated...

PACUPod: Oncology ·

2025/09/03

In this PACUPod episode, hosts Britany and Seth dissect the INAVO120 phase III trial evaluating inavolisib, a PI3K-alpha inhibitor, combined with palbociclib and fulvestrant in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. They discuss the clinical context, trial design (randomized, double-blind, placebo-controlled), patient population, endpoints (overall survival as primary, with progression-free survival and objective response rate as secondary), key

en

8:38

Comparison of outcomes with elranatamab and real...

PACUPod: Oncology ·

2025/09/03

en

6:40

Long acting lipegfilgrastim and antimicrobials as...

PACUPod: Oncology ·

2025/09/03

en

8:54

Effects of BojungikkiTang on immune response and...

PACUPod: Oncology ·

2025/09/03

en

7:58

Matching adjusted indirect comparison of tislelizumab...

PACUPod: Oncology ·

2025/09/03

en

7:56

Real-world patient profile and step-up dosing process...

PACUPod: Oncology ·

2025/09/03

en

2:18

First-line treatment with HDACis plus tislelizumab...

PACUPod: Oncology ·

2025/09/03

In this PACUPod update, Britany and Seth review Wang et al.'s phase II, single-arm trial of chidamide (an HDAC inhibitor) combined with tislelizumab (a PD-1 inhibitor) and platinum-based chemotherapy as first-line therapy for treatment-naïve, driver-gene-negative advanced NSCLC. They discuss the rationale for combining epigenetic therapy with immunotherapy and chemotherapy, the reported efficacy (ORR 80%, disease control rate 100%, median progression-free survival 11 months, median overall

en

9:24

Safety and preliminary efficacy of donor derived anti...

PACUPod: Oncology ·

2025/09/03

In this PACUPod update, Britany and Seth dive into a Phase I/II trial evaluating donor-derived WT1-targeted cytotoxic T lymphocytes (CTLs) for relapse prevention in children undergoing haploidentical hematopoietic stem cell transplantation. The discussion covers trial design (open-label, dose-escalation, single-arm), safety focus on graft-versus-host disease, and early signals of efficacy including relapse rates and CTL persistence. They highlight GMP manufacturing, timing within 60 days

en

6:57

Brentuximab vedotin plus chemotherapy for the...

PACUPod: Oncology ·

2025/09/03

en

7:31

Effectiveness and Safety of Immunotherapy for...

PACUPod: Oncology ·

2025/09/02

en

9:08

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated...

PACUPod: Oncology ·

2025/09/02

In this PACUPod episode, we dissect the BREAKWATER phase 3 trial that adds encorafenib and cetuximab to mFOLFOX6 as first-line therapy for patients with BRAF V600E-mutated metastatic colorectal cancer. The discussion covers study design, endpoints, and results comparing the triplet to standard chemotherapy (with or without bevacizumab). Key findings include improved progression-free survival (12.8 vs 7.1 months; HR 0.53) and overall survival (30.3 vs 15.1 months; HR 0.49), as well as a

en

7:24

Optimal treatment duration in metastatic renal cell...

PACUPod: Oncology ·

2025/09/02

en

7:40

Real world patient profile and step up dosing process...

PACUPod: Oncology ·

2025/09/02

en

7:56

Real-world patient profile and step-up dosing process...

PACUPod: Oncology ·

2025/09/01

en

102 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown